Medicinal composition for treating lung diseases, as well as preparation method and use of medicinal composition

A composition and drug technology, applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the single treatment angle, without considering the positive significance of increasing the oxygen absorption capacity of lung disease patients, the impact of lung disease treatment effect, etc. Problems, to achieve the effect of improving utilization rate and increasing absorption capacity

Active Publication Date: 2016-09-07
潘海英
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the medicines currently used clinically start from a single treatment point of view, without considering the positive significance of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating lung diseases, as well as preparation method and use of medicinal composition
  • Medicinal composition for treating lung diseases, as well as preparation method and use of medicinal composition
  • Medicinal composition for treating lung diseases, as well as preparation method and use of medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] A preparation method of a pharmaceutical composition for treating lung diseases

[0018] (1) Weigh percarbamide 0.15g, cortisone acetate 0.15g, dexamethasone 0.15g, N-acetylcysteine ​​0.3g, heparin sodium 0.3g and freeze-dry to make the water content less than 1% .

[0019] (2) Micronize percarbamide, cortisone acetate, dexamethasone, N-acetylcysteine, and sodium heparin using jet mill technology, so that the particle size of the powder is distributed within the range of 0.1 μm to 5 μm, Store at -10°C.

[0020] (3) 0.3 g of sorbitan trioleate, 0.75 g of 1,1,1,2-tetrafluoroethane (HFA134a) and 0.15 g of methylparaben were uniformly mixed with the micronized drug mixture.

[0021] (4) Cool the pharmaceutical composition to below -30°C, add it to the same container, stir, put it into 10 aerosol valves with a release range of 30 μl to 250 μl respectively, cover it and tighten it, and get the gas 10 cans of spray.

Embodiment 2

[0023] A preparation method of a pharmaceutical composition for treating lung diseases

[0024] (1) percarbamide 0.2g, cortisone acetate 0.8g, dexamethasone 0.6g, N-acetylcysteine ​​0.4g, heparin sodium 0.4g according to mass fraction ratio, carry out freeze-drying treatment, make it contain The amount of water is less than 1%.

[0025] (2) Micronize percarbamide, cortisone acetate, dexamethasone, N-acetylcysteine, and sodium heparin using jet mill technology, so that the particle size of the powder is distributed within the range of 0.1 μm to 5 μm, Store at -10°C.

[0026] (3) 0.2 g of sorbitan trioleate, 1.0 g of 1,1,1,2-tetrafluoroethane (HFA134a) and 0.2 g of methylparaben were uniformly mixed with the micronized drug mixture.

[0027] (4) Cool the pharmaceutical composition to below -30°C and add it to the same container, stir, put it into 20 aerosol valves with a drug release range of 30 μl to 250 μl respectively, cover it and tighten it, and get the gas 20 cans of sp...

Embodiment 3

[0029] A preparation method of a pharmaceutical composition for treating lung diseases

[0030] (1) According to 0.3g of percarbamide, 0.3g of cortisone acetate, 0.3g of dexamethasone, 0.6g of N-acetyl cysteine, and 0.6g of sodium heparin, the freeze-drying treatment is carried out to make the water content less than 1%.

[0031] (2) Micronize percarbamide, cortisone acetate, dexamethasone, N-acetylcysteine, and sodium heparin using jet mill technology, so that the particle size of the powder is distributed within the range of 0.1 μm to 5 μm, Store at -10°C.

[0032] (3) 0.3 g of sorbitan trioleate, 1.5 g of 1,1,1,2-tetrafluoroethane (HFA134a), 0.3 g of methylparaben and the micronized drug mixture were uniformly mixed.

[0033] (4) Cool the pharmaceutical composition to below -30°C and add it to the same container, stir it, put it into aerosol tanks with 30 aerosol valves with a drug release range of 30 μl to 250 μl, cover and tighten it, and get the gas 30 cans of spray. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Granularityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicinal composition for treating lung diseases, as well as a preparation method and use of the medicinal composition. The medicinal composition is prepared according to the proportion of carbamide: cortisone acetate: dexamethasone: N-acetyl-cysteine: heparin sodium: sorbitan tri-oleate: 1,1,1,2-tetrafluoroethane: methylparaben of 1:(1-4):(1-3):2:2:2:5:1, and is loaded into an aerosol can with a quantitative aerosol valve to prepare aerosol; active ingredients of the medicinal composition are subjected to freeze drying at first, then are micronized by adopting a high-energy ball mill or jet mill technology, and are loaded into the aerosol can of which the medicament release range of the quantitative aerosol valve is 30 to 250 microliters. The medicinal composition is directly administrated through the lung, so that the utilization rate of the medicinal composition is increased, anti-inflammation and antiviral effects are achieved, and meanwhile, the oxygen absorption of a patient is increased.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating lung diseases, a preparation method and application thereof. Background technique [0002] Chronic obstructive pulmonary disease is an important chronic respiratory disease with a large number of patients and a high mortality rate. After the acute attack period, the patient's clinical symptoms are relieved, but his lung function continues to deteriorate, and due to the decrease of his own defense and immune function and the influence of various harmful factors outside, the attack often occurs repeatedly, and gradually develops various symptoms. Cardiopulmonary complications. It is generally believed to be related to bronchial obstruction and protease-antiprotease imbalance. In conditions such as infection, the activity of proteases in the body increases. alpha 1 People with antitrypsin deficiency have a weakened ability to inhibit p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/573A61K31/198A61K31/727A61K31/327A61K9/12A61K9/72A61P11/00A61P29/00A61P31/02A61P31/04A61P9/00
CPCA61K9/0078A61K9/12A61K31/198A61K31/327A61K31/573A61K31/727A61K47/14A61K2300/00
Inventor 潘海英
Owner 潘海英
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap